{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T19:18:31Z","timestamp":1700421511076},"reference-count":6,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2685,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2001,3]]},"abstract":"<jats:p><jats:bold>Aims\u2002<\/jats:bold> To determine whether there is a pharmacokinetic interaction between the antiepileptic drugs remacemide and phenobarbitone.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> In a group of 12\u2003healthy adult male volunteers, the single dose and steady\u2010state kinetics of remacemide were each determined twice, once in the absence and once in the presence of phenobarbitone. The effect of 7\u2003days remacemide intake on initial steady\u2010state plasma phenobarbitone concentrations was also investigated.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Apparent remacemide clearance (CL\/<jats:italic>F<\/jats:italic>) and elimination half\u2010life values were unchanged after 7\u2003days intake of the drug in the absence of phenobarbitone (1.25\u2003\u00b1\u20030.32 <jats:italic>vs<\/jats:italic> 1.18\u2003\u00b1\u20030.22\u2003l\u2003kg<jats:sup>\u22121<\/jats:sup>\u2003h<jats:sup>\u22121<\/jats:sup> and 3.29\u2003\u00b1\u20030.68 <jats:italic>vs<\/jats:italic> 3.62\u2003\u00b1\u20030.85\u2003h, respectively). Concomitant administration of remacemide with phenobarbitone resulted in an increase in the estimated CL\/<jats:italic>F<\/jats:italic> of remacemide (1.25\u2003\u00b1\u20030.32 <jats:italic>vs<\/jats:italic> 2.09\u2003\u00b10.53\u2003l\u2003kg<jats:sup>\u22121<\/jats:sup>\u2003h<jats:sup>\u22121<\/jats:sup>), and a decreased remacemide half\u2010life (3.29\u2003\u00b1\u20030.68 <jats:italic>vs<\/jats:italic> 2.69\u2003\u00b1\u20030.33\u2003h). The elimination of the desglycinyl metabolite of remacemide also appeared to be increased after the phenobarbitone intake (half\u2010life 14.72\u2003\u00b1\u20032.82 <jats:italic>vs<\/jats:italic> 9.61\u2003\u00b1\u20035.51\u2003h, AUC 1532\u2003\u00b1\u2003258 <jats:italic>vs<\/jats:italic> 533\u2003\u00b1\u2003281\u2003ng\u2003ml<jats:sup>\u22121<\/jats:sup>\u2003h). Mean plasma phenobarbitone concentrations rose after 7\u2003days of continuing remacemide intake (12.67\u2003\u00b1\u20031.31 <jats:italic>vs<\/jats:italic> 13.86\u2003\u00b1\u20031.81\u2003\u03bcg ml<jats:sup>\u22121<\/jats:sup>).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Phenobarbitone induced the metabolism of remacemide and that of its desglycinyl metabolite. Remacemide did not induce its own metabolism, but had a modest inhibitory effect on the clearance of phenobarbitone.<\/jats:p>","DOI":"10.1046\/j.1365-2125.2001.00338.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:40:59Z","timestamp":1047357659000},"page":"249-255","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males"],"prefix":"10.1111","volume":"51","author":[{"given":"W. D.","family":"Hooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Eadie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. E.","family":"Blakey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Lockton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Manun'Ebo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(91)90050-P"},{"key":"e_1_2_6_3_2","first-page":"1035","volume-title":"Antiepileptic Drugs","author":"Clark B","year":"1995"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb01031.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)01005-4"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.292.6522.746"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04375.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2001.00338.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2001.00338.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.2001.00338.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:34:55Z","timestamp":1697524495000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.2001.00338.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["10.1046\/j.1365-2125.2001.00338.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.2001.00338.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}